Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from the multi-center MITRA-TUNE registry

Rubbio, Antonio Popolo; Testa, Luca; Grasso, Carmelo; Sisinni, Antonio; Tusa, Maurizio; Agricola, Eustachio; Marco, Federico De; Petronio, Anna Sonia; Montorfano, Matteo; Citro, Rodolfo; Adamo, Marianna; Mangieri, Antonio; Casenghi, Matteo; Milici, Anna Lisa; Stazzoni, Laura; Colombo, Antonio; Tamburino, Corrado; Bedogni, Francesco

doi:10.1016/j.ijcard.2021.11.027

Cited by 23 publications

(17 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar numbers (303 FMR patients, 40 with aFMR, 12.3%) were reported in a current retrospective study 20 . Furthermore, in the multicenter MITRA‐TUNE registry 7.5% had aFMR (1153 total FMR patients, 87 patients with aFMR) 21 . However, in our retrospective cohort of 154 patients with FMR and transcatheter mitral valve intervention we identified 41 patients with aFMR (26.6%).…”

Section: Discussionsupporting

confidence: 85%

Mitral valve edge‐to‐edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation

Rottländer

Golabkesh²,

Degen³

et al. 2022

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives: We aimed to compare indirect mitral annuloplasty using the Carillon Mitral Contour System and edge-to-edge repair via MitraClip in atrial functional mitral regurgitation (aFMR). Background: In patients with left ventricular dilation, both edge-to-edge repair and indirect mitral annuloplasty are effective in reducing mitral regurgitation, while no clinical trial has compared both interventional methods in aFMR. Methods: In a retrospective single-center analysis, 41 patients with aFMR underwent either edge-to-edge mitral valve repair (MitraClip group, n = 20) or indirect annuloplasty (Carillon group, n = 21). Results: Both treatment groups showed high procedural success (100%) and low complication rates. Both treatment groups showed a comparable reduction of New York Heart Association (NYHA) classification postimplantation, after 3-and 12months follow-up. Quantitative reduction in echocardiographic FMR parameters was significantly pronounced in the MitraClip group (reduction in vena contracta

show abstract

Section: Discussionsupporting

confidence: 85%

Mitral valve edge‐to‐edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation

Rottländer

Golabkesh²,

Degen³

et al. 2022

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…Prevention of left atrial dilation and restoration of sinus rhythm may be the key to treating atrial functional MR. Prospective trials comparing rhythm recovery with surgical/endovascular strategies are to be expected [ 76 , 77 , 78 ]. However, despite the minimally-invasive transfemoral approach, low mortality rate, and quick recovery after TMVr, some disadvantages inherent to this approach and to the complexity of MV disease and anatomy are undeniable.…”

Section: Current Challenges and Discussionmentioning

confidence: 99%

Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Zhang

Puehler

Søndergaard

et al. 2022

JCM

View full text Add to dashboard Cite

Over the last two decades, transcatheter devices have been developed to repair or replace diseased mitral valves (MV). Transcatheter mitral valve repair (TMVr) devices have been proven to be efficient and safe, but many anatomical structures are not compatible with these technologies. The most significant advantage of transcatheter mitral valve replacement (TMVR) over transcatheter repair is the greater and more reliable reduction in mitral regurgitation. However, there are also potential disadvantages. This review introduces the newest TMVr and TMVR devices and presents clinical trial data to identify current challenges and directions for future research.

show abstract

“…Atrial functional MR is a distinct entity most frequently observed in HFpEF 111,112 . New evidence supports M-TEER in this setting 112,113 …”

Section: Comorbidities and Special Conditionsmentioning

confidence: 92%

Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond – major changes are coming

Cimino

Pancaldi

Tomasoni

et al. 2022

Journal of Cardiovascular Medicine

Self Cite

View full text Add to dashboard Cite

Prevalence of heart failure is increasing worldwide mainly due to the ageing of the population and the improvement in diagnosis and treatment. In recent years, huge progress has been made in the management of heart failure patients. A new definition of chronic heart failure based on left ventricular ejection fraction and its possible trajectories has been reported. New drug classes have been introduced for the treatment of chronic heart failure. In particular, the prognostic benefit of sodium glucose co-transporter 2 inhibitors was demonstrated across all the heart failure phenotypes. Therapies for patients with advanced heart failure (long-term mechanical circulatory supports and heart transplantation) are now indicated also in the case of mild-to-moderate symptoms but with high risk of progression. In patients with acute heart failure, monitoring of urinary sodium and the use of acetazolamide may lead to better decongestion. Importantly, pre- and postdischarge assessment should lead to optimal treatment. Devices and telemonitoring can also be of help. Cardiovascular and noncardiovascular comorbidities are major determinants of the clinical course and need proper management. This review will summarize these important advances.

show abstract

Transcatheter edge-to-edge mitral valve repair in atrial functional mitral regurgitation: insights from the multi-center MITRA-TUNE registry

Cited by 23 publications

References 40 publications

Mitral valve edge‐to‐edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation

Mitral valve edge‐to‐edge repair versus indirect mitral valve annuloplasty in atrial functional mitral regurgitation

Transcatheter Mitral Valve Repair or Replacement: Competitive or Complementary?

Updates in heart failure: sodium glucose co-transporter 2 inhibitors and beyond – major changes are coming

Contact Info

Product

Resources

About